Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NLS Pharmaceutics ( (NLSP) ) has shared an update.
NLS Pharmaceutics Ltd. announced its Annual General Shareholders’ Meeting scheduled for June 30, 2025. Key agenda items include the re-election of KBT Treuhand AG as the independent proxy, approval of the 2024 financial statements, and the re-election of board members, among others. The company reported an operating loss for 2024, with a net loss of CHF -16,071,618, which will be carried forward. The resignation of Audrey Greenberg from the Board of Directors was noted, though the current board composition is deemed sufficient. The meeting will also address the re-election of auditors and the approval of compensation for board members.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a company based in Zurich, Switzerland, operating in the pharmaceutical industry. The company focuses on developing innovative therapies for the treatment of rare and complex central nervous system disorders.
Average Trading Volume: 203,586
Technical Sentiment Signal: Sell
Current Market Cap: $8.27M
For a thorough assessment of NLSP stock, go to TipRanks’ Stock Analysis page.